TheraPHIX™

About RNAssist

Founded in 2019 and based in Cambridge, UK, RNAssist has developed a versatile platform of non-crosslinking, low-toxicity stabilization reagents. Its core technology, based on deep eutectic solvents, enables simultaneous preservation of morphology, RNA, proteins, and post-translational modifications, addressing key sample degradation challenges in research and diagnostics. The company is commercializing several Research Use Only (RUO) and diagnostic products, with a growing community of over 300 evaluators, and is positioning its TheraPHIX™ solution for the stabilization of mRNA-LNP vaccines and therapeutics.